CBD Denver (CBDD) AI Stock Analysis

Top Page

CBD Denver

(Other OTC:CBDD)

Select Model

Rating:37Underperform

Action:N/A

Date:01/02/25

CBD Denver faces significant financial and operational challenges, with high leverage and cash flow issues as primary concerns. The lack of technical indicators and an extremely high P/E ratio indicate potential overvaluation. Limited information from the earnings call adds uncertainty, resulting in a low overall stock score.

Positive Factors

Product DiversificationA diverse product range allows CBD Denver to cater to various consumer preferences, enhancing market reach and reducing dependency on a single product line.

Negative Factors

High Debt LevelsHigh leverage and negative equity indicate financial risk, potentially limiting CBD Denver's ability to invest in growth opportunities and affecting long-term stability.

CBD Denver (CBDD) vs. SPDR S&P 500 ETF (SPY)

Not enough price history over this period.

Market Cap: $1.07M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -5.1
Beta (1Y): 133.27
Revenue Growth: -98.44%
EPS Growth: ―
Country: US
Employees: 2
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

CBD Denver Business Overview & Revenue Model

Company Description

CBD of Denver, Inc. engages in the cultivation, production, and distribution of cannabis flower and CBD products in Switzerland, Europe, and the US. Its brands include CBD Social Network, Black Peal CBD, and Rockflowr. The company was founded in 1993...

How the Company Makes Money

CBD Denver makes money primarily through the sale of its CBD-infused products to both retail and wholesale customers. The company generates revenue by distributing its products through various channels, including online direct-to-consumer sales, part...

CBD Denver Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CBDD against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
YCBD	46Neutral	$4.29M	-1.25	-34.25%	―	10.01%	95.01%
BJDX	44Neutral	$2.49M	-0.05	-125.01%	―	―	93.91%
DRMA	42Neutral	$3.84M	-0.18	-166.67%	―	―	88.77%
CBDD	37Underperform	$1.07M	-5.10	16.01%	―	-98.44%	―

* Healthcare Sector Average

Performance Comparison

CBDD and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CBDD	CBD Denver	―	―	―
YCBD	Cbdmd INc	0.38	-0.46	-54.52%
DRMA	Dermata Therapeutics, Inc.	0.78	-2.65	-77.34%
BJDX	Bluejay Diagnostics, Inc.	0.56	-6.56	-92.19%
CERO	Cero Therapeutics Holdings, Inc.	0.01	-0.11	-91.74%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jan 02, 2025

CBD Denver AI Stock Analysis